Loading clinical trials...
Loading clinical trials...
A Multi-center, One-arm Clinical Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive Advanced NSCLC. The Trial Aims to Evaluate the Efficacy and Safety of This Treatment.
Conditions
Interventions
Anlotinib Plus Icotinib
Locations
5
China
Hebei Provincial People's Hospital
Shijiazhuang, Hebei, China
Neimenggu Autonomous Region People's Hospital
Hohhot, Neimenggu, China
Neimenggu Medical University Affiliated Hospital
Hohhot, Neimenggu, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Start Date
December 1, 2018
Primary Completion Date
January 1, 2021
Completion Date
January 1, 2021
Last Updated
March 15, 2021
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions